Deargen

Deargen is a South Korean artificial intelligence-driven pharmaceutical technology company headquartered in Daejeon. It positions itself as an "AI-First Pharmatech" business focused on "transforming the future of treating the undruggables with AI." The company develops and applies deep learning platforms to multiple stages of early drug discovery, including genome data analysis, biomarker prediction, AI-powered target discovery, molecule selection, and lead optimization. Deargen's core technology platform is branded Dr.UG, an AI platform for drug discovery that specializes in genome data analysis, biomarker prediction, molecule selection, and optimization. The company states that it discovers new disease targets with Dr.UG and then designs small molecules for new drugs, aiming to realize precision medicine. Its pipeline spans several therapeutic modalities and strategies, including PROTAC, ADC, epitope, agonist, and inhibitor programs. Beyond its internal pipeline, Deargen pursues corporate partnerships and scientific collaborations. Its website highlights news of a partnership with Serengen to accelerate drug development, a patent application related to triple-negative breast cancer (TNBC), and a joint research agreement with Samsung Medical Center. These activities indicate a strategy that combines proprietary AI platforms, internal drug programs, and external collaborations with hospitals and biotechnology partners. Deargen is based in Daejeon, South Korea, a city known for its research institutions and biotechnology cluster. The company operates in the global pharmaceutical and biotechnology research market, offering AI-powered drug discovery capabilities to partners while advancing its own pipeline. Its public communications emphasize the use of deep learning to address difficult or previously "undruggable" targets.

Deargen is a South Korean company based in Daejeon that has developed an artificial intelligence platform for drug discovery. Public information about the company describes it as an "AI-First Pharmatech" venture focused on applying deep learning to the treatment of difficult or previously undruggable disease targets. The company's central technological asset is the Dr.UG platform, which it describes as an AI platform for developing new drugs based on Deargen's deep learning technology. Dr.UG specializes in genome data analysis, biomarker prediction, molecule selection, and optimization. Within this platform, Deargen has developed or branded specific capabilities including DearTRANS for genome data analysis, WX for biomarker prediction, DearDTI for molecule selection, and MolEQ for lead optimization. Together these tools support AI-powered target discovery and AI-powered drug design. Deargen's stated approach is to discover new disease targets using Dr.UG and then design small molecules for new drugs, with the goal of realizing precision medicine. Its pipeline covers multiple treatment strategies and modalities, including PROTAC, ADC, epitope, agonist, and inhibitor programs. This breadth suggests that the company is pursuing both small-molecule and newer therapeutic modalities. In addition to internal research, Deargen has pursued external partnerships and collaborations. Its website highlights a partnership with Serengen to accelerate drug development, a patent application related to triple-negative breast cancer (TNBC), and a joint research agreement with Samsung Medical Center. These collaborations point to a business model that combines proprietary AI platforms, internal drug discovery programs, and partnerships with hospitals and biotechnology companies. Deargen is headquartered in Daejeon, South Korea, a location associated with research institutions and a growing biotechnology sector. The company operates in the global pharmaceutical and biotechnology research market, offering AI-powered drug discovery capabilities and advancing its own pipeline. Detailed information about its founding date, founders, ownership structure, and financing history is not available in the provided evidence.

• Deargen and Serengen announce a partnership to accelerate drug development.

• Deargen announces a patent application related to triple-negative breast cancer (TNBC).

• Deargen and Samsung Medical Center sign a joint research agreement.

AI-First Pharmatech transforming the future of treating the undruggables with AI.

• Dr.UG

  AI platform for drug discovery based on Deargen's deep learning technology, specializing in genome data analysis, biomarker prediction, molecule selection, and optimization.

• DearTRANS

  Genome data analysis component of the Dr.UG platform.

• WX

  Biomarker prediction component of the Dr.UG platform.

• DearDTI

  Molecule selection component of the Dr.UG platform.

• MolEQ

  Lead optimization component of the Dr.UG platform.

1. 1디어젠 | Deargen Inc.deargen.me
2. 2Deargen (South Korea) - Wikidatawikidata.org